# Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)

> **NCT06291103** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **University Hospital, Rouen** · enrollment: 290 (estimated)

## Conditions studied

- Kidney Transplant Rejection

## Interventions

- **DRUG:** Conversion to Belatacep
- **DRUG:** Standard of care treatment (SOC regimen) with Tacrolimus

## Key facts

- **NCT ID:** NCT06291103
- **Lead sponsor:** University Hospital, Rouen
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2032-04-01
- **Final completion:** 2032-04-01
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06291103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06291103, "Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06291103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*